The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial

Strezova, Ana; Lal, Himal; Enweonye, Igwebuike; Cámpora, Laura; Beukelaers, Pierre; Segall, Nathan; Heineman, Thomas C.; Schuind, Anne; Oostvogels, Lidia

doi:10.1016/j.vaccine.2019.08.001

Cited by 16 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study provides real-world evidence that individuals who receive RZV concomitantly with other vaccines do not have reduced protection against HZ. These findings are consistent with immunogenicity data from randomized clinical trials, which found no evidence of immunologic interference when RZV was administered concomitantly with Tdap, IIV4, or PPSV23 [ 14–16 ]. Together, these data support recommendations allowing for concomitant vaccination of RZV with other vaccines in eligible adults.…”

Section: Discussionsupporting

confidence: 86%

“…However, real-world observational studies reported no difference in the risk of HZ among individuals who received PPSV23 and ZVL concomitantly and those who received the vaccines ≥4 weeks apart [ 11 , 12 ], and ACIP continued to recommend concomitant vaccination of ZVL with other vaccines for eligible persons [ 13 ]. In randomized controlled trials, coadministration of RZV with other vaccines (ie, tetanus, diphtheria, and acellular pertussis vaccine [Tdap], quadrivalent inactivated influenza vaccine [IIV4], and PPSV23) did not interfere with humoral immune responses, and no safety concerns were identified [ 14–16 ].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination

Bruxvoort

Qian

et al. 2022

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background The 2-dose recombinant zoster vaccine (RZV) series is recommended for prevention of herpes zoster (HZ) in adults aged ≥50 years, but data are limited on the impact of concomitant administration with other vaccines on subsequent HZ risk. Methods This cohort study included Kaiser Permanente Southern California members aged ≥50 years who received 2 doses of RZV 4 weeks to ≤6 months apart during 1 April 2018–30 September 2019. RZV recipients with and without same-day concomitant vaccination for either RZV dose were followed up for incident HZ beginning 31 days after the second RZV dose until 30 September 2020. The hazard ratio (HR) for HZ comparing RZV recipients with and without concomitant vaccination was estimated using Cox proportional hazards regression, adjusting for confounders. Results RZV with and without concomitant vaccination was received by 12 898 and 28 353 individuals, respectively. HZ occurred among 41 individuals with concomitant vaccination (incidence rate, 2.2 [95% confidence interval {CI}, 1.6–3.0] per 1000 person-years) and 136 without concomitant vaccination (3.4 [95% CI, 2.9–4.0] per 1000 person-years). The adjusted HR for HZ comparing RZV recipients with and without concomitant vaccination was 0.75 (95% CI, .53–1.08). Conclusions HZ risk was not significantly different between RZV recipients with and without concomitant vaccination, supporting recommendations allowing for concomitant administration of RZV with other vaccines.

show abstract

Section: Discussionsupporting

confidence: 86%

mentioning

confidence: 99%

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination

Bruxvoort

Qian

et al. 2022

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Recombinant and adjuvanted vaccines, such as RZV, can be administered concomitantly, at different anatomic sites, with other adult vaccines, including COVID-19 vaccines (17). Concomitant administration of RZV with other adult vaccines ¶ ¶ ¶ ¶ has been studied, and there was no evidence for interference in the immune response to either vaccine or of safety concerns (18)(19)(20). Coadministration of RZV with adjuvanted influenza vaccine (Fluad) and COVID-19 vaccines is being studied.…”

Section: Clinical Guidance § § § §mentioning

confidence: 99%

Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

Anderson¹,

Masters²,

Guo³

et al. 2022

MMWR Morb. Mortal. Wkly. Rep.

112

View full text Add to dashboard Cite

show abstract

“…Simultaneous administration of vaccines is also cost-effective and convenient for both healthcare providers and vaccinees, primarily due to the lower number of healthcare visits required when compared to sequential administration. 19 Previous studies have shown that RZV may be co-administered with other routine adult vaccines, such as the quadrivalent seasonal inactivated influenza vaccine (IIV4), 20 the tetanus-diphtheriapertussis vaccine (Tdap), 21 or PPSV23. 22 The safety results observed in these co-administration studies were consistent with the known safety profile of RZV.…”

Section: Introductionmentioning

confidence: 99%

“…No immune interference was observed between RZV and these co-administered vaccines except for a reduced response to one of five Tdap antigens (pertactin), the clinical significance of which is unknown. [20][21][22] Here, we evaluated coadministration of the first RZV dose with PCV13 in adults ≥50 YOA, aiming to demonstrate non-inferiority of humoral immune responses to these two vaccines when co-administered compared to sequential administration and to evaluate the safety of their coadministration.…”

Section: Introductionmentioning

confidence: 99%

The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial

Min

Mwakingwe-Omari

Riley

et al. 2022

Journal of Infection

View full text Add to dashboard Cite

Background: Herpes zoster (HZ) results from reactivation of latent varicella-zoster virus. Adults at increased risk of HZ (due to immunocompromising conditions or older age) are also at risk of pneumococcal disease, both of which are preventable by vaccination. We evaluated simultaneous versus sequential administration of the adjuvanted recombinant zoster vaccine (RZV) and the 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ≥50 years. Methods: In this phase IIIB multinational trial (NCT03439657), participants were randomized 1:1 to receive either the first RZV dose and PCV13 simultaneously followed by the second RZV dose two months later (Co-Ad, N = 449), or at two-month intervals, PCV13, the first RZV dose, and the second RZV dose sequentially (Control, N = 463). Objectives were to demonstrate that immune responses to both vaccines are non-inferior when co-administered compared to sequential administration and to evaluate the safety of their co-administration. Results:The RZV vaccine response rate (VRR) in the Co-Ad group was 99.1% (95% confidence interval [CI]: 97.6-99.7), meeting the VRR success criterion. Non-inferiority criteria for the Co-Ad versus Control group were also met for anti-glycoprotein E antibodies (adjusted geometric mean concentration Control/Co-Ad ratio 1.07 [95%CI: 0.99-1.16]) and all PCV13 serotypes (adjusted antibody geometric mean titer Control/Co-Ad ratios 1.

show abstract

The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial

Cited by 16 publications

References 36 publications

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination

Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial

Contact Info

Product

Resources

About